, Volume 70, Issue 10, pp 1215–1230 | Cite as

Optimal Antagonism of the Renin-Angiotensin-Aldosterone System

Do We Need Dual or Triple Therapy?
  • Christian Werner
  • Janine Pöss
  • Michael BöhmEmail author
Current Opinion


The cardiovascular and cardiorenal disease continuum comprises the transition from cardiovascular risk factors to endothelial dysfunction and atherosclerosis, to clinical complications such as myocardial infarction (MI) and stroke, to the development of persistent target-organ damage and, ultimately, to chronic congestive heart failure (CHF), end-stage renal disease or premature death. The renin-angiotensin-aldosterone system (RAAS) is involved in all steps along this pathway, and RAAS blockade with ACE inhibitors or angiotensin AT1-receptor antagonists (angiotensin receptor blockers; ARBs) has turned out to be beneficial for patient outcomes throughout the disease continuum. Both ACE inhibitors and ARBs can prevent or reverse endothelial dysfunction and atherosclerosis, thereby reducing the risk of cardiovascular events. These drugs have further been shown to reduce end-organ damage in the heart, kidneys and brain. Aldosterone antagonists such as spironolactone and eplerenone are increasingly recognized as a third class of RAAS inhibitor with potent risk-reducing properties, especially but not solely with respect to the inhibition of cardiac remodelling and the possible prevention of heart failure.

In secondary prevention, head-to-head comparisons of ACE inhibitors and ARBs, such as the recent ONTARGET study, provided evidence that, in addition to better tolerability, ARBs are non-inferior to ACE inhibitors in the prevention of clinical endpoints such as MI and stroke in cardiovascular high-risk patients. However, the combination of both ramipril and telmisartan at the maximally tolerated dosage achieved no further benefits and was associated with more adverse events such as symptomatic hypotension and renal dysfunction. In acute MI complicated by heart failure, the VALIANT trial has shown similar effects of ACE inhibition with captopril and ARB treatment with valsartan, but dual RAAS blockade did not further reduce events. In CHF, meta-analyses of RESOLVD, ValHeFT and CHARM-ADDED have shown that combined RAAS inhibition with an ACE inhibitor and ARB significantly reduced the morbidity endpoint in certain patient subgroups compared with standard therapy. However, in clinical practice, dual RAAS blockade is rarely employed, as seen, for instance, in the CORONA trial. The RALES and EPHESUS trials, investigating the effects of aldosterone blockade on cardiovascular outcomes in CHF patients, revealed that the addition of an aldosterone antagonist to standard heart failure therapy conferred powerful relative risk reductions for both morbidity and mortality. Future studies will elucidate whether this also holds true for patients who are asymptomatic or who have heart failure with preserved ejection fraction.

In selected patients with renal disease, several studies have suggested that combined RAAS blockade brings about additional renoprotective antiproteinuric effects independent of blood pressure reduction, and large trials with robust endpoints are underway.

In summary, combined therapy with several RAAS inhibitors is not recommended for all patients along the cardiorenovascular continuum. Patients with CHF with incomplete neuroendocrine blockade, as indicated, for example, by repetitive cardiac decompensation or refractory symptoms, might benefit from dual therapy as long as safety issues are well controlled. Finally, novel pharmacological agents such as the direct renin inhibitor aliskiren may provide additional therapeutic tools, but their role has yet to be established.


Congestive Heart Failure Valsartan Telmisartan Aliskiren Eplerenone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.


  1. 1.
    Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 1991; 121 (4 Pt 1): 1244–63PubMedCrossRefGoogle Scholar
  2. 2.
    Okunishi H, Miyazaki M, Toda N. Evidence for a putatively new angiotensin II-generating enzyme in the vascular wall. J Hypertens 1984; 2(3): 277–84PubMedCrossRefGoogle Scholar
  3. 3.
    Nickenig G, Harrison DG. The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis. Part I: oxidative stress and atherogenesis. Circulation 2002; 105(3): 393–6PubMedCrossRefGoogle Scholar
  4. 4.
    Nickenig G, Harrison DG. The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis. Part II: AT(1) receptor regulation. Circulation 2002; 105(4): 530–6PubMedCrossRefGoogle Scholar
  5. 5.
    van de Wal RM, van Veldhuisen DJ, van Gilst WH, et al. Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense? Eur Heart J 2005 Nov; 26(22): 2361–7PubMedCrossRefGoogle Scholar
  6. 6.
    Steckelings UM, Rettig R, Unger T. Angiotensin in the kidney: a key to understanding hypertension? Cell Metab 2007; 5(1): 7–8PubMedCrossRefGoogle Scholar
  7. 7.
    Unger T, Stoppelhaar M. Rationale for double reninangiotensin-aldosterone system blockade. Am J Cardiol 2007; 100(3A):25J–31PubMedCrossRefGoogle Scholar
  8. 8.
    Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 2004 Aug 5;351(6): 585–92PubMedCrossRefGoogle Scholar
  9. 9.
    Cohen SA, Jondeau G, Beauvais F, et al. Beneficial effects of carvedilol on angiotensin-converting enzyme activity and renin plasma levels in patients with chronic heart failure. Eur J Heart Fail 2004 Jun; 6(4): 463–6CrossRefGoogle Scholar
  10. 10.
    Sealey JE, Laragh JH. Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. Am J Hypertens 2007; 20(5): 587–97PubMedCrossRefGoogle Scholar
  11. 11.
    Menard J, Azizi M. The difficult conception, birth and delivery of a renin inhibitor: controversies around aliskiren. J Hypertens 2007; 25(9): 1775–82PubMedCrossRefGoogle Scholar
  12. 12.
    Schefe JH, Menk M, Reinemund J, et al. A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein. Circ Res 2006; 99(12): 1355–66PubMedCrossRefGoogle Scholar
  13. 13.
    Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28(12): 1462–536PubMedGoogle Scholar
  14. 14.
    Doulton TW, He FJ, Macgregor GA. Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 2005; 45(5): 880–6PubMedCrossRefGoogle Scholar
  15. 15.
    Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369(9557): 201–7PubMedCrossRefGoogle Scholar
  16. 16.
    Perticone F, Ceravolo R, Pujia A, et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001; 104(2): 191–6PubMedCrossRefGoogle Scholar
  17. 17.
    Schmieder RE. Endothelial dysfunction: how can one intervene at the beginning of the cardiovascular continuum? J Hypertens Suppl 2006; 24(2): S31–5PubMedCrossRefGoogle Scholar
  18. 18.
    Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345(12): 870–8PubMedCrossRefGoogle Scholar
  19. 19.
    Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106(6): 672–8PubMedCrossRefGoogle Scholar
  20. 20.
    Schmieder RE, Hilgers KF, Schlaich MP, et al. Reninangiotensin system and cardiovascular risk. Lancet 2007; 369(9568): 1208–19PubMedCrossRefGoogle Scholar
  21. 21.
    Dell’Italia LJ, Meng QC, Balcells E, et al. Increased ACE and chymase-like activity in cardiac tissue of dogs with chronic mitral regurgitation. Am J Physiol 1995 Dec; 269 (6 Pt 2): H2065–73PubMedGoogle Scholar
  22. 22.
    Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensinconverting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342(3): 145–53PubMedCrossRefGoogle Scholar
  23. 23.
    Lonn E, Shaikholeslami R, Yi Q, et al. Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction: a substudy of the Heart Outcomes Prevention Evaluation (HOPE) trial. J Am Coll Cardiol 2004; 43(12): 2200–6PubMedCrossRefGoogle Scholar
  24. 24.
    Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359(9311): 995–1003PubMedCrossRefGoogle Scholar
  25. 25.
    Hoshida S, Kato J, Nishino M, et al. Increased angiotensinconverting enzyme activity in coronary artery specimens from patients with acute coronary syndrome. Circulation 2001; 103(5): 630–3PubMedCrossRefGoogle Scholar
  26. 26.
    Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358(15): 1547–59PubMedCrossRefGoogle Scholar
  27. 27.
    Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008 Sep 27; 372(9644): 1174–83PubMedCrossRefGoogle Scholar
  28. 28.
    Verdecchia P, Sleight P, Mancia G, et al., ONTARGET/TRANSCEND Investigators. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease. Circulation 2009 Oct 6; 120(14): 1380–9PubMedCrossRefGoogle Scholar
  29. 29.
    Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009 Apr 14; 53(15): e1–90PubMedCrossRefGoogle Scholar
  30. 30.
    Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure). Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112(12): e154–235PubMedCrossRefGoogle Scholar
  31. 31.
    Arnold JM, Yusuf S, Young J, et al. Prevention of heart failure in patients in the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation 2003; 107(9): 1284–90PubMedCrossRefGoogle Scholar
  32. 32.
    Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362(9386): 782–8PubMedCrossRefGoogle Scholar
  33. 33.
    Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensinconverting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351(20): 2058–68PubMedCrossRefGoogle Scholar
  34. 34.
    Zanchetti A, Julius S, Kjeldsen S, et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. J Hypertens 2006; 24(11): 2163–8PubMedCrossRefGoogle Scholar
  35. 35.
    Mochizuki S, Dahlof B, Shimizu M, et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, openlabel, blinded endpoint morbidity-mortality study. Lancet 2007; 369(9571): 1431–9PubMedCrossRefGoogle Scholar
  36. 36.
    Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal trial in myocardial infarction with angiotensin II antagonist losartan. Lancet 2002; 360(9335): 752–60PubMedCrossRefGoogle Scholar
  37. 37.
    Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987 Jun 4; 316(23): 1429–35CrossRefGoogle Scholar
  38. 38.
    Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure: the SOLVD Investigators. N Engl J Med 1991; 325(5): 293–302CrossRefGoogle Scholar
  39. 39.
    Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival And Ventricular Enlargement trial: the SAVE Investigators. N Engl J Med 1992; 327(10): 669–77PubMedCrossRefGoogle Scholar
  40. 40.
    Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure: the Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993; 342(8875): 821–8Google Scholar
  41. 41.
    Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction: Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995; 333(25): 1670–6PubMedCrossRefGoogle Scholar
  42. 42.
    Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial. The Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355(9215): 1582–7PubMedCrossRefGoogle Scholar
  43. 43.
    van de Wal RM, Plokker HW, Lok DJ, et al. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int J Cardiol 2006; 106(3): 367–72PubMedCrossRefGoogle Scholar
  44. 44.
    Rouleau JL, Moye LA, de Champlain J, et al. Activation of neurohumoral systems following acute myocardial infarction. Am J Cardiol 1991 Nov 18; 68(14): 80D–6PubMedCrossRefGoogle Scholar
  45. 45.
    Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008 Aug 16; 372(9638): 547–53PubMedCrossRefGoogle Scholar
  46. 46.
    Kunz R, Friedrich C, Wolbers M, et al. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008 Jan 1; 148(1): 30–48PubMedGoogle Scholar
  47. 47.
    Berl T. Review: renal protection by inhibition of the reninangiotensin-aldosterone system. J Renin Angiotensin Aldosterone Syst 2009 Mar; 10(1): 1–8PubMedCrossRefGoogle Scholar
  48. 48.
    Fried LF, Duckworth W, Zhang JH, et al. Design of combination angiotensin receptor blocker and angiotensinconverting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). Clin J Am Soc Nephrol 2009 Feb; 4(2): 361–8PubMedCrossRefGoogle Scholar
  49. 49.
    Group TCTS. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316(23): 1429–35CrossRefGoogle Scholar
  50. 50.
    Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensinconverting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362(9386): 772–6PubMedCrossRefGoogle Scholar
  51. 51.
    Solomon SD, Wang D, Finn P, et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 2004; 110(15): 2180–3PubMedCrossRefGoogle Scholar
  52. 52.
    McMurray J, Solomon S, Pieper K, et al. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol 2006; 47(4): 726–33PubMedCrossRefGoogle Scholar
  53. 53.
    McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensinconverting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362(9386): 767–71PubMedCrossRefGoogle Scholar
  54. 54.
    Solomon SD, Skali H, Anavekar NS, et al. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. Circulation 2005; 111(25): 3411–9PubMedCrossRefGoogle Scholar
  55. 55.
    Califf RM, Lokhnygina Y, Velazquez EJ, et al. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial). Am J Cardiol 2009 Jul 15; 104(2): 151–7PubMedCrossRefGoogle Scholar
  56. 56.
    Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349(20): 1893–906PubMedCrossRefGoogle Scholar
  57. 57.
    McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999; 100(10): 1056–64PubMedCrossRefGoogle Scholar
  58. 58.
    Krum H, Carson P, Farsang C, et al. Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. Eur J Heart Fail 2004 Dec; 6(7): 937–45PubMedCrossRefGoogle Scholar
  59. 59.
    Lakhdar R, Al-Mallah MH, Lanfear DE. Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and metaanalysis of randomized controlled trials. J Card Fail 2008 Apr; 14(3): 181–8PubMedCrossRefGoogle Scholar
  60. 60.
    Hoppe UC. Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? AT1-receptor antagonists? Clin Res Cardiol 2007; 96(4): 196–8PubMedCrossRefGoogle Scholar
  61. 61.
    Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357(22): 2248–61PubMedCrossRefGoogle Scholar
  62. 62.
    Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003 Apr 3; 348(14): 1309–21PubMedCrossRefGoogle Scholar
  63. 63.
    Chapman N, Dobson J, Wilson S, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007 Apr; 49(4): 839–45PubMedCrossRefGoogle Scholar
  64. 64.
    Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999 Sep 2; 341(10): 709–17PubMedCrossRefGoogle Scholar
  65. 65.
    Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004 Aug 5; 351(6): 543–51PubMedCrossRefGoogle Scholar
  66. 66.
    Adamopoulos C, Ahmed A, Fay R, et al. Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial. Eur J Heart Fail 2009 Nov; 11(11): 1099–105PubMedCrossRefGoogle Scholar
  67. 67.
    Ezekowitz JA, McAlister FA. Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. Eur Heart J 2009 Feb; 30(4): 469–77PubMedCrossRefGoogle Scholar
  68. 68.
    Pitt B, Bakris G, Ruilope LM, et al. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 2008 Oct 14; 118(16): 1643–50PubMedCrossRefGoogle Scholar
  69. 69.
    Pitt B. Aldosterone blockade in patients with heart failure and a reduced left ventricular ejection fraction. Eur Heart J 2009 Feb; 30(4): 387–8PubMedCrossRefGoogle Scholar
  70. 70.
    Mak GJ, Ledwidge MT, Watson CJ, et al. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. J Am Coll Cardiol 2009 Oct 27; 54(18): 1674–82PubMedCrossRefGoogle Scholar
  71. 71.
    Montezano AC, Touyz RM. Networking between systemic angiotensin II and cardiac mineralocorticoid receptors. Hypertension 2008 Dec; 52(6): 1016–8PubMedCrossRefGoogle Scholar
  72. 72.
    A comparison of outcomes in patients in New York Heart Association (NYHA) class II heart failure when treated with eplerenone or placebo in addition to standard heart failure medicines (EMPHASIS-HF) [ identifier NCT00232180]. US National Institutes of Health, [online]. Available from URL: [Accessed 2009 Nov 30]
  73. 73.
    Aldosterone antagonist therapy for adults with heart failure and preserved systolic function (TOPCAT) [Clinical identifier NCT00094302]. US National Institutes of Health, [online]. Available from URL: [Accessed 2009 Nov 30]
  74. 74.
    Lee HY, Oh BH. Cardio-renal protection with aliskiren, a direct renin inhibitor, in the ASPIRE HIGHER program. Expert Rev Cardiovasc Ther 2009 Mar; 7(3): 251–7PubMedCrossRefGoogle Scholar
  75. 75.
    Sever PS, Gradman AH, Azizi M. Managing cardiovascular and renal risk: the potential of direct renin inhibition. J Renin Angiotensin Aldosterone Syst 2009 Jun; 10(2): 65–76PubMedCrossRefGoogle Scholar
  76. 76.
    Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008 Jun 5; 358(23): 2433–46PubMedCrossRefGoogle Scholar
  77. 77.
    McMurray JJ, Pitt B, Latini R, et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008 May; 1(1): 17–24PubMedCrossRefGoogle Scholar
  78. 78.
    Solomon SD, Appelbaum E, Manning WJ, et al. Effect of the direct Renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009 Feb 3; 119(4): 530–7PubMedCrossRefGoogle Scholar
  79. 79.
    Jacobshagen C, Westermann D, Holubarsch C, et al. Hotline update of clinical trials and registries presented at the American College of Cardiology Congress 2010: ACCORD, INVEST, NAVIGATOR, RACE II, SORT OUT III, CSP-474, DOSE, ASPIRE and more. Clin Res Cardiol 2010 Jun; 99(6): 337–44. Epub 2010 Apr 16PubMedCrossRefGoogle Scholar
  80. 80.
    Dusing R, Sellers F. ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial. Curr Med Res Opin 2009 Sep; 25(9): 2287–301PubMedCrossRefGoogle Scholar
  81. 81.
    Chrysant SG, Murray AV, Hoppe UC, et al. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis. Curr Med Res Opin 2008 Apr; 24(4): 1039–47PubMedCrossRefGoogle Scholar
  82. 82.
    McAlpine HM, Cobbe SM. Neuroendocrine changes in acute myocardial infarction. Am J Med 1988 Mar 11; 84(3A): 61–6PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  1. 1.Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische IntensivmedizinUniversitätsklinikum des SaarlandesHomburg SaarGermany

Personalised recommendations